<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T21:59:22Z</responseDate><request verb="GetRecord" identifier="oai:digital.lib.washington.edu:1773/35199" metadataPrefix="dim">https://digital.lib.washington.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:digital.lib.washington.edu:1773/35199</identifier><datestamp>2026-02-15T22:48:30Z</datestamp><setSpec>com_1773_4888</setSpec><setSpec>col_1773_4918</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Wald, Anna</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" authority="259a91c3-3467-4127-a9a2-16a408030eae" confidence="300">Yager, Jessica Eve</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2016-03-11T22:39:48Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2016-03-11T22:39:48Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2016-03-11</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="submitted">2015-12</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">Yager_washington_0250O_15268.pdf</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/1773/35199</dim:field>
   <dim:field mdschema="dc" element="description">Thesis (Master's)--University of Washington, 2015-12</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">Epstein-Barr virus (EBV), a common herpesvirus, is the main causative agent of infectious mononucleosis. Following primary infection, EBV persists in host cells and can cause B cell transformation, leading to the development of EBV-associated malignancies. The role for antiviral therapy in treating and preventing EBV-associated disease remains unclear. Using oral swabs collected from a randomized, double-blind, placebo-controlled crossover study that our group had previously conducted, we sought to determine the impact of valganciclovir on both the rate and quantity of oral EBV shedding. Twenty-six men were randomly assigned to receive either oral valganciclovir, 900mg daily, or oral placebo once daily for eight weeks. Participants then received no study drug for a two week “washout period,” followed by the alternate treatment (valganciclovir or placebo) for a second eight-week period. Valganciclovir reduced the proportion of days on which EBV was detected by 72% (relative risk 0.28, 95% confidence interval 0.08-0.55; p=0.003), and reduced the quantity of virus detected by 0.77 logs (95% confidence interval 0.62-0.91 logs; p&lt;0.001). These results were consistent regardless of participants’ HIV status and use of antiretroviral therapy. These findings could have significant clinical applications in both the treatment and prevention of EBV-associated disease.</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en_US</dim:field>
   <dim:field mdschema="dc" element="subject">antiviral prophylaxis; asymptomatic shedding; Epstein-Barr virus; post-transplant lymphoproliferative disorder; valganciclovir</dim:field>
   <dim:field mdschema="dc" element="subject" qualifier="other">Epidemiology</dim:field>
   <dim:field mdschema="dc" element="subject" qualifier="other">Virology</dim:field>
   <dim:field mdschema="dc" element="subject" qualifier="other">Medicine</dim:field>
   <dim:field mdschema="dc" element="subject" qualifier="other">epidemiology</dim:field>
   <dim:field mdschema="dc" element="title">Valganciclovir for the Suppression of Epstein-Barr Virus Replication</dim:field>
   <dim:field mdschema="dc" element="type">Thesis</dim:field>
   <dim:field mdschema="dc" element="embargo" qualifier="terms">Open Access</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>